KM Research Hub

FIXED FIVE-YEAR COHORT AUDIT

近五年文献重新检索与对照

旧查询复现与严格 v3 为主比较;历史库存和广召回仅用于解释差异与检查漏检。

complete · complete 汇总 CSV 明细 CSV
固定日期2021-07-29 至 2026-07-29
入排版本oncology-definitive-rct-km-v3
并集论文20925
批次键five-year-20210729-20260729-v1

四个独立队列

数字为批次中保存的原始 PMID 数,不会随着日常监测改变。

历史库存参照组 13065 audit_reference · server-inventory-snapshot-v1
旧查询复现组 7069 primary_legacy · legacy-phase3-fulltext-v1
严格 v3 主组 4707 primary_new · oncology-phase3-survival-strict-v3
v3 广召回影子组 13640 recall_audit · oncology-phase3-survival-discovery-v3

集合关系

交集和差集均按 PMID 精确计算;DOI 只用于明细核对。

比较交集左组独有右组独有
历史库存 ↔ 旧查询复现 7028 6037 41
旧查询复现 ↔ 严格 v3 2464 4605 2243
严格 v3 ↔ 广召回影子组 4707 0 8933
严格查询未命中、但影子组经 v3 筛选后合格 166 篇

元数据入排

20925 / 20925 已完成

KM 证据

仅检查 v3 元数据合格论文,不运行曲线数字化。

论文明细

共 17654 篇;可组合筛选集合关系、入排结果和 KM 证据。

论文队列集合关系v3 入排KM 证据
Buparlisib and Paclitaxel in Patients with Head and Neck Squamous Cell Carcinoma: Immunogenomic Biomarkers of Efficacy from the BERIL-1 Study. PMID 39808408 · Target Oncol · 2025-Mar 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Meta-Analysis of Placebo-Treated Patients: Dropout Rates From Treatment in MASH Randomised Controlled Trials. PMID 39807647 · Aliment Pharmacol Ther · 2025-Mar 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H
仅历史库存 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Impact of Frailty on Antihypertensive Treatment in Older Adults. PMID 39807596 · Hypertension · 2025-Mar 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Human leukocyte antigen alloimmunization in a randomized trial of amustaline/glutathione pathogen-reduced red cells in complex cardiac surgery patients. PMID 39801369 · Transfusion · 2025-Mar 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Heart failure outcomes captured by adverse event reporting in participants with type 2 diabetes and atherosclerotic cardiovascular disease: Observations from the VERTIS CV trial. PMID 39792342 · Eur J Heart Fail · 2025-Mar 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Alkaline phosphatase decline and pain response as predictors of overall survival benefit in patients treated with radium-223: a post hoc analysis of the REASSURE study. PMID 39789153 · Br J Cancer · 2025-Mar 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
A Perspective on the MARS2 Trial. PMID 39772349 · J Thorac Oncol · 2025-Mar 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H S B
严格 v3 独有 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Outcome following pylorus resecting pancreaticoduodenectomy versus classical Whipple's pancreaticoduodenectomy: a randomised controlled trial. PMID 39757070 · HPB (Oxford) · 2025-Mar The study is a randomized controlled trial comparing two surgical techniques (pylorus resecting vs. classical pancreaticoduodenectomy) for pancreatic cancer. It meets oncology, human, randomized, and original result criteria. However, it is not a Phase III or definitive trial (phase is not specified), lacks a drug-containing intervention (surgical procedure only), and the primary endpoint is a short-term postoperative complication (delayed gastric emptying), not a time-to-event efficacy endpoint like OS or PFS. Therefore, it does not meet the eligibility criteria for inclusion.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Vanzacaftor-tezacaftor-deutivacaftor versus elexacaftor-tezacaftor-ivacaftor in individuals with cystic fibrosis aged 12 years and older (SKYLINE Trials VX20-121-102 and VX20-121-103): results from two randomised, active-controlled, phase 3 trials. PMID 39756424 · Lancet Respir Med · 2025-Mar 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Effect of telemedicine support for intraoperative anaesthesia care on postoperative outcomes: the TECTONICS randomised clinical trial. PMID 39753404 · Br J Anaesth · 2025-Mar 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Priors and decision thresholds in phase 2 and phase 3 randomized controlled trials evaluating drug efficacy using Bayesian methods: a systematic review. PMID 39724990 · J Clin Epidemiol · 2025-Mar 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H
仅历史库存 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Mechanistic Learning for Predicting Survival Outcomes in Head and Neck Squamous Cell Carcinoma. PMID 39722558 · CPT Pharmacometrics Syst Pharmacol · 2025-Mar 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Determinants of Liraglutide Treatment Discontinuation in Type 1 Diabetes: A Post Hoc Analysis of ADJUNCT ONE and ADJUNCT TWO Randomized Placebo-Controlled Clinical Studies. PMID 39717993 · J Diabetes Sci Technol · 2025-Mar 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L
旧查询独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Reference Ranges and Determinants of Thyroid Function and TSH Receptor Antibodies During Early Pregnancy in Nepal. PMID 39676726 · Clin Endocrinol (Oxf) · 2025-Mar 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
SB16 versus reference denosumab in postmenopausal women with osteoporosis: 18-month outcomes of a phase III randomized clinical trial. PMID 39674388 · Bone · 2025-Mar 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Early vs later non-vitamin K antagonist oral anticoagulants in patients with acute ischemic stroke and atrial fibrillation: A meta-analysis and systematic review of randomized trials. PMID 39672479 · Heart Rhythm · 2025-Mar 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H
仅历史库存 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
High Omega-3, Low Omega-6 Diet With Fish Oil for Men With Prostate Cancer on Active Surveillance: The CAPFISH-3 Randomized Clinical Trial. PMID 39671538 · J Clin Oncol · 2025-Mar The record describes a randomized Phase II oncology trial with a drug/supplement intervention (fish oil) and a primary biomarker endpoint (Ki-67). It is not a Phase III/IIIb trial, and the primary endpoint is not a time-to-event efficacy outcome. Therefore, it does not meet the eligibility criteria.
H L S B
旧组与严格 v3 交集 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Extending the time window for tenecteplase by effective reperfusion of penumbral tissue in patients with large vessel occlusion: Rationale and design of a multicenter, prospective, randomized, open-label, blinded-endpoint, controlled phase 3 trial. PMID 39654273 · Int J Stroke · 2025-Mar 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Sarcoma: Last Year's Practice Changing Papers. PMID 39648237 · Ann Surg Oncol · 2025-Mar 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H S B
严格 v3 独有 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Efficacy and safety of lemborexant in subjects with insomnia disorder receiving medications for depression or anxiety symptoms. PMID 39632341 · Neuropsychopharmacol Rep · 2025-Mar 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L
旧查询独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Efficacy and Safety of KH903 Plus FOLFIRI as a Second-Line Treatment in Unresectable Recurrent or Metastatic Colorectal Cancer: A Randomized Phase 2 Study. PMID 39632230 · Clin Colorectal Cancer · 2025-Mar 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Dupilumab Efficacy and Safety in Children With Moderate to Severe Asthma and High Blood Eosinophils: A Post Hoc Analysis of VOYAGE. PMID 39613097 · J Allergy Clin Immunol Pract · 2025-Mar 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L
旧查询独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Quality of life in advanced-stage, asymptomatic, non-bulky follicular lymphoma treated with rituximab shows significant improvement compared with watchful-waiting. PMID 39604791 · Br J Haematol · 2025-Mar The record describes a Phase III randomized trial in follicular lymphoma with a drug intervention (rituximab). However, the reported results are focused exclusively on quality of life outcomes, which are not time-to-event efficacy endpoints as required for inclusion.
H L S B
旧组与严格 v3 交集 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Influence of the type of anaesthesia on acute kidney injury after nephrectomy: a randomised controlled trial. PMID 39592204 · Anaesthesia · 2025-Mar The record is a randomized trial in oncology patients with a drug intervention, but the primary efficacy endpoint is acute kidney injury (a safety/toxicity endpoint), not a time-to-event oncologic efficacy endpoint (OS, PFS, DFS, EFS, RFS, TTP). No time-to-event data (Kaplan-Meier, HR) are reported for any oncologic endpoint.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Myelofibrosis symptom assessment form total symptom score version 4.0: measurement properties from the MOMENTUM phase 3 study. PMID 39585603 · Qual Life Res · 2025-Mar The record describes a psychometric validation study of a symptom assessment form within a Phase III trial, not a report of the trial's drug efficacy results. It does not contain the required primary or key secondary time-to-event endpoint data.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Intermittent or Continuous Panitumumab Plus Fluorouracil, Leucovorin, and Irinotecan for First-Line Treatment of RAS and BRAF Wild-Type Metastatic Colorectal Cancer: The IMPROVE Trial. PMID 39576946 · J Clin Oncol · 2025-Mar 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Effect of intraperitoneal ropivacaine during and after cytoreductive surgery on time-interval to adjuvant chemotherapy in advanced ovarian cancer: a randomised, double-blind phase III trial. PMID 39572271 · Br J Anaesth · 2025-Mar The trial is a randomized Phase III study with a drug intervention and original results, but the primary endpoint (time to return to intended oncologic therapy) is not a standard time-to-event efficacy endpoint (OS, PFS, DFS, EFS, RFS, TTP) and does not involve Kaplan-Meier analysis or hazard ratios, which are required for inclusion in this cohort.
H L S B
旧组与严格 v3 交集 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Quality of life and testosterone recovery after androgen deprivation therapy in high-risk prostate cancer patients: long-term data from a phase III trial. PMID 39565556 · Qual Life Res · 2025-Mar The report is a secondary analysis of a Phase III randomized trial in prostate cancer, focusing on quality of life and testosterone recovery. It does not have a primary or key secondary time-to-event efficacy endpoint (OS, PFS, DFS, etc.) or Kaplan-Meier/HR analysis. Additionally, the intervention (ADT) is standard hormonal therapy, not a novel drug intervention meeting the criteria.
H L B
旧查询独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Long-Term Outcomes of Primary Chemoablation of Low-Grade Upper Tract Urothelial Carcinoma With UGN-101, a Mitomycin Reverse Thermal Gel. PMID 39561384 · J Urol · 2025-Mar The record describes a long-term follow-up analysis of a single-arm Phase III trial. It is an original report with drug intervention and oncology setting, but it lacks a randomized comparator and does not report a primary or key secondary time-to-event efficacy endpoint (OS, PFS, DFS, etc.) with Kaplan-Meier or HR. The primary endpoint of the original trial appears to be complete response rate (a binary outcome). Therefore, it does not meet the eligibility criteria for a randomized trial with a time-to-event endpoint.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Cost-effectiveness of Enasidenib versus conventional care for older patients with IDH2-mutant refractory/relapsed AML. PMID 39560957 · Leuk Lymphoma · 2025-Mar 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H S B
严格 v3 独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Progression to complete retinal pigment epithelium and outer retinal atrophy (cRORA): post hoc analysis of the GATHER1 trial. PMID 39538001 · Graefes Arch Clin Exp Ophthalmol · 2025-Mar 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L
旧查询独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
ONS-5010 (bevacizumab-vikg) Safety and Efficacy in Subfoveal Choroidal Neovascularization Secondary to Age-related Macular Degeneration. PMID 39535413 · Ophthalmic Surg Lasers Imaging Retina · 2025-Mar 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Short-course subcutaneous treatment with birch pollen allergoids greatly improves symptom and medication scores in birch allergy. PMID 39520181 · Allergy · 2025-Mar 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Population pharmacokinetics and exposure-response relationships of dostarlimab in primary advanced or recurrent endometrial cancer in part 1 of RUBY. PMID 39520048 · Br J Clin Pharmacol · 2025-Mar The record is from a randomized trial (RUBY) that meets many criteria but does not explicitly state the phase as Phase III/IIIb or Phase II/III in the provided metadata. The deterministic review flagged this as 'phase3_evidence_unclear'. The report's primary focus is pharmacokinetics and exposure-response, not the formal primary efficacy analysis of the trial.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Phase II Randomized Study of Maintenance Atezolizumab Versus Atezolizumab Plus Talazoparib in Patients With SLFN11 Positive Extensive-Stage SCLC: S1929. PMID 39505259 · J Thorac Oncol · 2025-Mar 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
The SQ tree sublingual immunotherapy tablet is effective and well tolerated in children-A pivotal phase III trial. PMID 39495086 · Allergy · 2025-Mar 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
A phase 3 randomized trial of sulopenem vs. ertapenem in patients with complicated intra-abdominal infections. PMID 39491784 · Clin Microbiol Infect · 2025-Mar 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Cost-Utility Analysis of Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin Chemotherapy Regimen in Comparison With Gemcitabine and Cisplatin Chemotherapy Regimen in the Treatment of Patients With Muscle Invasive Bladder Cancer in Iran. PMID 39480370 · Value Health Reg Issues · 2025-Mar 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H S B
严格 v3 独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Efficacy of ultrasound-guided bilateral rectus sheath block vs. local anesthetic infiltration in gynecologic oncology patients undergoing midline laparotomy: a triple-blinded randomized controlled trial. PMID 39480232 · Minerva Anestesiol · 2025-Mar The record describes a randomized controlled trial comparing two local anesthetic techniques for postoperative pain management in gynecologic oncology surgery. While it is a randomized trial in human oncology patients, it does not meet several key eligibility criteria: the phase is not established as Phase III/IIIb or Phase II/III, the intervention is a non-drug-only procedural technique (ultrasound-guided rectus sheath block vs. local anesthetic wound infiltration), and the primary endpoints are pain scores and analgesic consumption, which are not time-to-event efficacy outcomes (e.g., OS, PFS, DFS, EFS, RFS, TTP) with Kaplan-Meier or HR reporting.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Statin use and oncological outcomes in a propensity-matched cohort of nonmetastatic castration resistant prostate cancer patients of the ARAMIS trial. PMID 39477770 · Urol Oncol · 2025-Mar 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L S B
旧组与严格 v3 交集 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
An international multicentre randomised controlled trial of en bloc resection of bladder tumour vs conventional transurethral resection of bladder tumour: first results of the en bloc resection of urothelium carcinoma of the bladder (EBRUC) II trial. PMID 39462182 · BJU Int · 2025-Mar This is an original, randomized, oncology trial reporting primary results. However, it is excluded because it does not involve a drug-containing intervention (it compares surgical techniques) and does not report a primary/key secondary time-to-event efficacy endpoint (e.g., OS, PFS, DFS, with KM or HR). The 'recurrence rates' mentioned are not presented as KM curves or with a hazard ratio.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
The effect of Plasmodium falciparum exposure and maternal anti-circumsporozoite protein antibodies on responses to RTS,S/AS01E vaccination in infants and children: an ancillary observational immunological study to a phase 3, randomised clinical trial. PMID 39461358 · Lancet Infect Dis · 2025-Mar 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Immunogenicity of a booster dose of a bivalent (Asp614Gly and omicron BA.4/5 variant) self-amplifying mRNA SARS-CoV-2 booster vaccine versus the BNT162b2 omicron BA.4/5 mRNA vaccine: a randomised phase 3 trial. PMID 39461355 · Lancet Infect Dis · 2025-Mar 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Exposure-Response Analysis of Tofacitinib in Active Psoriatic Arthritis: Results from Two Phase 3 Studies. PMID 39453735 · J Clin Pharmacol · 2025-Mar 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L
旧查询独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Immediate effects of propofol on mood: a randomized comparison of two doses in a cohort with depression. PMID 39417860 · Psychopharmacology (Berl) · 2025-Mar 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Exposure-Efficacy Analysis and Dopamine D2 Receptor Occupancy in Adults with Schizophrenia after Treatment with the Monthly Intramuscular Injectable Risperidone ISM. PMID 39417209 · J Clin Pharmacol · 2025-Mar 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
A Phase II/III multicenter randomized single blind non-inferiority immunogenicity and safety study of TeddyVac™ vaccine of Human Biologicals Institute in healthy subjects of 10 years to 60 years of age. PMID 39378070 · Infect Dis (Lond) · 2025-Mar 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Introducing new antibiotics for multidrug-resistant bacteria: obstacles and the way forward. PMID 39374649 · Clin Microbiol Infect · 2025-Mar 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H
仅历史库存 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Re: Peritoneal Flap for Lymphocele Prophylaxis Following Robotic-assisted Radical Prostatectomy with Lymph Node Dissection: The Randomised Controlled Phase 3 PELYCAN Trial. PMID 39368904 · Eur Urol · 2025-Mar 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Prostate Cancer-related Events in Patients with Synchronous Metastatic Hormone-sensitive Prostate Cancer Treated with Androgen Deprivation Therapy with and Without Concurrent Radiation Therapy to the Prostate; Data from the HORRAD Trial. PMID 39304427 · Eur Urol · 2025-Mar The report describes a secondary analysis of a randomized controlled trial in oncology. While it is human, oncology, randomized, and reports a time-to-event endpoint (local event-free survival), it lacks a drug-containing intervention (radiotherapy is a non-drug intervention) and the primary endpoint is not a key efficacy endpoint (OS, PFS, DFS, etc.). Therefore, it does not meet all eligibility criteria.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -